AbOliGo Closes Oversubscribed Round to Accelerate Multiomic Research Tools and Appoints Proven Life Sciences Board CAMBRIDGE, UK – August, 2025 – AbOliGo , a biotechnology company pioneering high-performance antibody-oligonucleotide conjugates (AOCs), today announced the successful close of an oversubscribed seed ... 6 Aug 2025